Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-04-15
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to study the drug LPX-TI641 in patients with atopic dermatitis and psoriasis. We will compare the safety and tolerability of LPX-TI641 to placebo( a look-alike solution) that contains no drug. We will also evaluate the plasma pharmacokinetics of LPX-TI641. LPX-TI641 (or placebo) will be administered as an oral solution for 28 days.